NCT04201990

Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung Cancer

An Exploratory Study on the Safety and Efficacy of Cryoablation Combined With Camrelizumab and Apatinib in the Treatment of Multiprimary Lung Cancer With Non-known Driving Genes

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: ShiYue Li · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Objective: This study is to observe the safety and therapeutic effect of cryoablation combined with pd-1 antibody immunotherapy and anti-angiogenesis therapy in multiple primary lung cancer (MPLC) patients. Methods: In this study, 20 patients with MPLC who conform to the admission criteria are enrolled and began to receive treatment with Camrelizumab combined with Apatinib after cryoablation.

Detailed description

Subjects who meet the admission criteria will be treated with Camrelizumab and Apatinib until disease progression, intolerable toxicity, death, withdrawal of the patient or the researchers determined that the drug must be discontinued. The primary end point of this study is safety of cryoablation combined with carillizumab and apatinib for MPLC. The secondary endpoints include objective response rate, disease control rate, time to progression, progression free survival and overall survival. Exploratory endpoint is to explore biomarkers in tumor tissue and blood that could potentially predict the efficacy of Camrelizumab and Apatinib.

Conditions

• Lung Cancer

Interventions

Type	Name	Description
DRUG	Camrelizumab and Apatinib	Camrelizumab, iv, Q3W; Apatinib, po, QD

Timeline

• Start date: 2019-12-01
• Primary completion: 2021-12-01
• Completion: 2022-12-01
• First posted: 2019-12-17
• Last updated: 2019-12-17